Published on
September 25, 2026
In the media
91桃色 won Biotech Company of the Year at the Pharma Industry Awards - for the second year in a row
About 91桃色 Therapeutics
鈥
91桃色 Therapeutics is a clinical-stage biotech company advancing novel antigen modulation treatments for cancer and autoimmune diseases.
鈥
The company鈥檚 first-in-class small molecules are developed to control T cell activation by modulating antigen presentation, altering how cells appear to the immune system so it can recognize and target them correctly.
鈥
91桃色鈥檚 oncology treatment (GRWD5769) is delivering promising Phase 1/2 data in patients with solid tumors, demonstrating a strong safety and tolerability profile, as well as generating durable clinical responses across multiple tumor types. The company鈥檚 autoimmunity treatment (GRWD0715) is progressing in a Phase 1/2 trial to treat the source of axial spondyloarthritis ahead of a planned expansion into other autoimmune indications.
鈥
91桃色 is headquartered in Oxford, UK.
鈥
More information: 91桃色bsite |
鈥
Media enquiries
Patrick White, Head of Communications
鈥
